Strategic Acquisition Nexcelom was acquired by PerkinElmer for 260 million in May 2021, indicating a potential channel and integration opportunity through PerkinElmer's broader distributor network and customer base in biotech and pharma.

High Throughput Oncology Product strengths in high throughput image cytometry (Celigo and Cellaca MX) align with cancer research and translational science labs pursuing scalable cell counting, viability, and morphology analysis.

Broad Customer Footprint Existing user base spans academic institutes, pharmaceutical, and biotech companies, suggesting opportunities to upsell consumables, reagents, and advanced imaging workflows across multiple research verticals.

Integrated Tech Stack Adoption of cloud and enterprise tools (AWS, SAP, Azure DevOps, OneTrust) enables scalable sales motions, customer success, and data-driven demonstrations for life science customers seeking robust, compliant instrument deployments.

Global Growth Potential Boston-area headquarters with 80+ global employees and ongoing innovations in image cytometry position Nexcelom to expand in international markets through strategic partnerships and expanded service/support capabilities.